Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 96-100

  Vergaro, Giuseppe ^a,b,d   Franco, Annamaria Del ^a   Giannoni, Alberto ^a   Prontera, Concetta ^a   Ripoli, Andrea ^a   Barison, Andrea ^a   Masci, Pier Giorgio ^a   Aquaro, Giovanni Donato ^a   Solal, Alain Cohen ^c   Padeletti, Luigi ^d   Paßino, Claudio ^a,b   Emdin, Michele ^a,b,d  

^a CNR   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c University of Paris   (France)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biomarkers; Cardiomyopathy; Dilated; Late gadolinium enhancement; Magnetic resonance imaging; Myocardial fibrosis

Indexed keywords

GADOLINIUM; GALECTIN 3; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART STROKE VOLUME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC DILATED CARDIOMYOPATHY; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION; AGED; BLOOD; CARDIOMYOPATHY, DILATED; COHORT ANALYSIS; FIBROSIS; HEART MUSCLE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; BIOMARKERS; CARDIOMYOPATHY, DILATED; COHORT STUDIES; FEMALE; FIBROSIS; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PROSPECTIVE STUDIES;

EID: 84933512178     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.02.008     Document Type: Article

References (29)

1. D.L. Mann, M.R. Bristow, Mechanisms and models in heart failure: The biomechanical model and beyond, Circulation 111 (2005) 2837-2849.
2. P.G. Masci, R. Schuurman, A. Barison, et al., Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: A contrast-enhanced cardiovascular magnetic study, Circ. Cardiovasc. Imaging 6 (2013) 790-799.
3. J.J. McMurray, Clinical practice. Systolic heart failure, N. Engl. J. Med. 362 (2010) 228-238.
4. R. Gary, L. Davis, Diastolic heart failure, Heart Lung 37 (2008) 405-416.
5. P.G. Masci, A. Barison, G.D. Aquaro, et al., Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy, Int. J. Cardiol. 157 (2012) 43-47.
6. A. Gulati, A. Jabbour, T.F. Ismail, et al., Aßociation of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy, JAMA 309 (2013) 896-908.
7. U.C. Sharma, S. Pokharel, T.J. van Brakel, et al., Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation 110 (2004) 3121-3128.
8. R.A.Weir, C.J. Petrie, C.A. Murphy, et al., Galectin-3 and cardiac function in survivors of acute myocardial infarction, Circ. Heart Fail. 6 (2013) 492-498.
9. R.A. de Boer, D.J. Lok, T. Jaarsma, et al., Predictive value of plasma galectin-3 levels in heart failurewith reduced and preserved ejection fraction, Ann. Med. 43 (2011) 60-68.
10. D.J. Lok, P. Van Der Meer, P.W. de la Porte, et al., Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study, Clin. Res. Cardiol. 99 (2010) 323-328.
11. D.J. Lok, S.I. Lok, P.W. Bruggink-André de la Porte, et al., Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure, Clin. Res. Cardiol. 102 (2013) 103-110.
12. L. Calvier, M. Miana, P. Reboul, et al., Galectin-3 mediates aldosterone-induced vascular fibrosis, Arterioscler. Thromb. Vasc. Biol. 33 (2013) 67-75.
13. P. Richardson, W. McKenna, M. Bristow, et al., Report of the 1995World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Claßification of Cardiomyopathies, Circulation 93 (1996) 841-842.
14. M. Emdin, C. Paßino, C. Prontera, et al., Cardiac natriuretic hormones, neurohormones, thyroid hormones and cytokines in normal subjects and patients with heart failure, Clin. Chem. Lab. Med. 42 (2004) 627-636.
15. L. Yu, W.P. Ruifrok, M. Meißner, et al., Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis, Circ. Heart Fail. 6 (2013) 107-117.
16. P.G. Masci, C. Doulaptsis, E. Bertella, et al., The incremental prognostic value ofmyocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure, Circ. Heart Fail. 7 (2014) 448-456.
17. N.Mewton, C.Y. Liu, P. Croisille, D.Bluemke, J.A. Lima, Aßeßment ofmyocardial fibrosis with cardiovascular magnetic resonance, J. Am. Coll. Cardiol. 57 (2011) 891-903.
18. C.G. Brilla, L.S. Matsubara, K.T. Weber, Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension, Am. J. Cardiol. 71 (1993) 12A-16A.
19. F. Zannad, B. Doußet, F. Alla, Treatment of congestive heart failure: Interfering the aldosterone-cardiac extracellular matrix relationship, Hypertension 38 (2001) 1227-1232.
20. W.C. Roberts, R.J. Siegel, B.M. McManus, Idiopathic dilated cardiomyopathy: Analysis of 152 necropsy patients, Am. J. Cardiol. 60 (1987) 1340-1355.
21. S. Takashio, M. Yamamuro, T. Uemura, et al., Correlation between extent of myocardial fibrosis aßeßed by cardiac magnetic resonance and cardiac troponin T release in patients with nonischemic heart failure, Am. J. Cardiol. 113 (2014) 1697-1704.
22. M. Guglin, S. Verma, Right side of heart failure, Heart Fail. Rev. 17 (2012) 511-527.
23. B.H. Freed, M. Gomberg-Maitland, S. Chandra, et al., Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension, J. Cardiovasc. Magn. Reson. 14 (2012) 11.
24. L. Iles, H. Pfluger, L. Lefkovits, et al., Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death, J. Am. Coll. Cardiol. 57 (2011) 821-828.
25. N.C. Henderson, T. Sethi, The regulation of inflammation by galectin-3, Immunol. Rev. 230 (2009) 160-171.
26. F. Azibani, L. Benard, S. Schloßarek, et al., Aldosterone inhibits antifibrotic factors in mouse hypertensive heart, Hypertension 59 (2012) 1179-1187.
27. J.E. Ho, C. Liu, A. Lyaß, et al., Galectin-3, amarker of cardiac fibrosis, predicts incident heart failure in the community, J. Am. Coll. Cardiol. 60 (2012) 1249-1256.
28. D.A.Morrow, M.L. O'Donoghue, Galectin-3 in cardiovascular disease: A poßiblewindow into early myocardial fibrosis, J. Am. Coll. Cardiol. 60 (2012) 1257-1258.
29. B. Ky, B. French, K. McCloskey, et al., Cappola TP. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure, Circ. Heart Fail. 4 (2011) 180-187.